Shannon M Dunlay1, Véronique L Roger2, Jill M Killian3, Susan A Weston3, Philip J Schulte3, Anna V Subramaniam4, Saul B Blecker5, Margaret M Redfield6. 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Dunlay.shannon@mayo.edu. 2. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Population Health and Medicine, New York University Langone, New York, New York, USA. 6. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
OBJECTIVES: The goal of this study was to evaluate the prevalence, characteristics, and outcomes of patients with advanced heart failure (HF) in a geographically defined population. BACKGROUND: Some patients with HF progress to advanced HF, characterized by debilitating HF symptoms refractory to therapy. Limited data are available on the epidemiology and outcomes of patients with advanced HF. METHODS: This was a population-based cohort study of all Olmsted County, Minnesota, adults with and without HF from 2007 to 2017. The 2018 European Society of Cardiology advanced HF diagnostic criteria were operationalized and applied to all patients with HF. Hospitalization and mortality in advanced HF, overall and according to ejection fraction (EF) type (reduced EF <40% [HFrEF], mid-range EF 40%-49% [HFmrEF], and preserved EF ≥50% [HFpEF]) were examined using Andersen-Gill and Cox models. RESULTS: Of 6,836 adults with HF, 936 (13.7%) met criteria for advanced HF. The prevalence of advanced HF increased with age and was higher in men. At advanced HF diagnosis, 396 (42.3%) patients had HFrEF, 134 (14.3%) had HFmrEF, and 406 (43.4%) had HFpEF. The median (interquartile range) time from advanced HF diagnosis to death was 12.2 months (3.7-29.9 months). The mean rate of hospitalization was 2.91 (95% CI: 2.78-3.06) per person-year in the first year after advanced HF diagnosis. There were no differences in risks of all-cause mortality or hospitalization by EF. Patients with advanced HFpEF were at lower risk for cardiovascular mortality compared with advanced HFrEF (HR: 0.79; 95% CI: 0.65-0.97). CONCLUSIONS: In this population-based study, more than one-half of patients with advanced HF had mid-range or preserved EF, and survival was poor regardless of EF.
OBJECTIVES: The goal of this study was to evaluate the prevalence, characteristics, and outcomes of patients with advanced heart failure (HF) in a geographically defined population. BACKGROUND: Some patients with HF progress to advanced HF, characterized by debilitating HF symptoms refractory to therapy. Limited data are available on the epidemiology and outcomes of patients with advanced HF. METHODS: This was a population-based cohort study of all Olmsted County, Minnesota, adults with and without HF from 2007 to 2017. The 2018 European Society of Cardiology advanced HF diagnostic criteria were operationalized and applied to all patients with HF. Hospitalization and mortality in advanced HF, overall and according to ejection fraction (EF) type (reduced EF <40% [HFrEF], mid-range EF 40%-49% [HFmrEF], and preserved EF ≥50% [HFpEF]) were examined using Andersen-Gill and Cox models. RESULTS: Of 6,836 adults with HF, 936 (13.7%) met criteria for advanced HF. The prevalence of advanced HF increased with age and was higher in men. At advanced HF diagnosis, 396 (42.3%) patients had HFrEF, 134 (14.3%) had HFmrEF, and 406 (43.4%) had HFpEF. The median (interquartile range) time from advanced HF diagnosis to death was 12.2 months (3.7-29.9 months). The mean rate of hospitalization was 2.91 (95% CI: 2.78-3.06) per person-year in the first year after advanced HF diagnosis. There were no differences in risks of all-cause mortality or hospitalization by EF. Patients with advanced HFpEF were at lower risk for cardiovascular mortality compared with advanced HFrEF (HR: 0.79; 95% CI: 0.65-0.97). CONCLUSIONS: In this population-based study, more than one-half of patients with advanced HF had mid-range or preserved EF, and survival was poor regardless of EF.
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur J Heart Fail Date: 2016-05-20 Impact factor: 15.534
Authors: Clyde W Yancy; Henry Krum; Barry M Massie; Marc A Silver; Lynne Warner Stevenson; Mei Cheng; Sun Sook Kim; Rosemary Evans Journal: Am Heart J Date: 2007-04 Impact factor: 4.749
Authors: Walter A Rocca; Brett J Peterson; Shannon K McDonnell; James H Bower; J Eric Ahlskog; Daniel J Schaid; Demetrius M Maraganore Journal: Neuroepidemiology Date: 2005-01-25 Impact factor: 3.282
Authors: Behram P Mody; Mohammed Hasan Khan; Syed Zaid; Chul Ahn; Amanda Lloji; Wilbert S Aronow; Chhaya A Gupta; Avi Levine; Alan L Gass; Howard A Cooper; Gregg M Lanier Journal: Am J Ther Date: 2020-10-01 Impact factor: 2.688
Authors: M Packer; J R Carver; R J Rodeheffer; R J Ivanhoe; R DiBianco; S M Zeldis; G H Hendrix; W J Bommer; U Elkayam; M L Kukin Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245
Authors: Shannon M Dunlay; Margaret M Redfield; Susan A Weston; Terry M Therneau; Kirsten Hall Long; Nilay D Shah; Véronique L Roger Journal: J Am Coll Cardiol Date: 2009-10-27 Impact factor: 24.094
Authors: Samuel S Gidding; Donald Lloyd-Jones; Joao Lima; Bharat Ambale-Venkatesh; Sanjiv J Shah; Ravi Shah; Cora E Lewis; David R Jacobs; Norrina B Allen Journal: Circ Heart Fail Date: 2019-09-11 Impact factor: 8.790
Authors: Daniela Tomasoni; Julie K K Vishram-Nielsen; Matteo Pagnesi; Marianna Adamo; Carlo Mario Lombardi; Finn Gustafsson; Marco Metra Journal: ESC Heart Fail Date: 2022-03-30
Authors: Anna V Subramaniam; Susan A Weston; Jill M Killian; Phillip J Schulte; Veronique L Roger; Margaret M Redfield; Saul B Blecker; Shannon M Dunlay Journal: Circ Heart Fail Date: 2022-03-25 Impact factor: 10.447
Authors: Daniele Masarone; Andrea Petraio; Antonio Fiorentino; Santo Dellegrottaglie; Fabio Valente; Ernesto Ammendola; Gerardo Nigro; Giuseppe Pacileo Journal: Front Cardiovasc Med Date: 2022-02-16
Authors: Shannon M Dunlay; Saul Blecker; Phillip J Schulte; Margaret M Redfield; Che G Ngufor; Amy Glasgow Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2022-03-29
Authors: Nicholas Y Tan; Veronique L Roger; Jill M Killian; Yong-Mei Cha; Peter A Noseworthy; Shannon M Dunlay Journal: J Am Heart Assoc Date: 2021-12-22 Impact factor: 6.106